AstraZeneca Acquire Amolyt Pharma

AstraZeneca declared that the purchase of Amolyt Pharma, a clinical-stage biotechnology firm dedicated to creating cutting-edge therapies for uncommon endocrine disorders, had been completed successfully.

Eneboparatide, a Phase III investigational therapeutic peptide with a distinctive mechanism of action intended to meet important medical objectives for hypoparathyroidism, is a noteworthy addition to the purchase, which strengthens the Alexion, AstraZeneca Rare Disease late-stage pipeline and builds on its bone metabolism series.

AstraZeneca has paid up to $1.05 billion in cash and debt-free compensation for all of Amolyt Pharma’s shares in circulation, as per the conditions of the comprehensive arrangement. This involves the opportunity for Amolyt Pharma’s shareholders to be given a further conditional payment of $250 million paid upon the completion of a certain regulatory milestone, as well as to the $800 million upfront upon transaction close.